RBCC Looks Overseas for Potentially Lucrative Licensing Opportunities

  RBCC Looks Overseas for Potentially Lucrative Licensing Opportunities

Business Wire

NOKOMIS, Fla. -- April 24, 2013

In a bid to expand the market for its biotech innovations beyond North
America, Rainbow Coral Corp. (OTCBB: RBCC) is seeking out new overseas targets
that stand to benefit from adding licenses for the drug delivery protocols
that its joint venture partner, TheraKine, has developed.

Some experts believe that the worldwide market for the 10 most popular drug
delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.
TheraKine is a leader in this marketplace, having developed and patented
novel, tunable technologies with the potential to enable selective,
site-specific drug delivery that allow for lower drug concentrations and
significantly reduced risk of drug toxicity.

In order to build market share in this fast-growing sector, RBCC is looking
for overseas healthcare providers for whom TheraKine’s advanced
sustained-release delivery system could yield significant returns for their

“Licensing is the key to making this a successful partnership with TheraKine,”
said RBCC CEO Patrick Brown. “Together, we can spread this revolutionary
technology around the globe to the doctors and patients who need it most.”

For more information on Rainbow BioSciences’ personalized medicine
initiatives, please visitwww.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology
innovations to compete alongside companies such as Bristol Myers Squibb Co.
(NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT)
and Amgen Inc. (NASDAQ:AMGN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visitwww.RainbowBioSciences.com. For investment information and
performance data on the Company, please

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.


Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
Press spacebar to pause and continue. Press esc to stop.